| Effect | Increase |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 157 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44, 45-64 |
In persons with schizophrenia and tardive dyskinesia (TD), supplementation of 240mg EGb-761 daily for 12 weeks is able to increase circulating BDNF concentrations and reduce symptoms of TD, but only in Val/Met heterozygotes.
